Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis

Joseph H. Helm, John T. Miura, Jason A. Glenn, Rebecca K. Marcus, Gregory Larrieux, Thejus T. Jayakrishnan, Amy E. Donahue, T. Clark Gamblin, Kiran K. Turaga, Fabian Johnston

Research output: Contribution to journalReview article

Abstract

Background: Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature. Methods: The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots. Results: Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49–55), with 59 % (54–67) female. The median peritoneal carcinomatosis index score was 19 (16–23). Complete cytoreduction (CC0, 1) was performed in 67 % (46–93 %) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 %, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 %) and those receiving cisplatin intraperitoneal chemotherapy alone (48 %) or in combination (44 %) had an improved 5-year survival. Conclusions: While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.

Original languageEnglish (US)
Pages (from-to)1686-1693
Number of pages8
JournalAnnals of Surgical Oncology
Volume22
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Meta-Analysis
Drug Therapy
Survival
Cisplatin
Publication Bias
Observational Studies
Malignant Mesothelioma
Epidemiology
Carcinoma
Mortality

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma : A Systematic Review and Meta-analysis. / Helm, Joseph H.; Miura, John T.; Glenn, Jason A.; Marcus, Rebecca K.; Larrieux, Gregory; Jayakrishnan, Thejus T.; Donahue, Amy E.; Gamblin, T. Clark; Turaga, Kiran K.; Johnston, Fabian.

In: Annals of Surgical Oncology, Vol. 22, No. 5, 01.05.2015, p. 1686-1693.

Research output: Contribution to journalReview article

Helm, JH, Miura, JT, Glenn, JA, Marcus, RK, Larrieux, G, Jayakrishnan, TT, Donahue, AE, Gamblin, TC, Turaga, KK & Johnston, F 2015, 'Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis', Annals of Surgical Oncology, vol. 22, no. 5, pp. 1686-1693. https://doi.org/10.1245/s10434-014-3978-x
Helm, Joseph H. ; Miura, John T. ; Glenn, Jason A. ; Marcus, Rebecca K. ; Larrieux, Gregory ; Jayakrishnan, Thejus T. ; Donahue, Amy E. ; Gamblin, T. Clark ; Turaga, Kiran K. ; Johnston, Fabian. / Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma : A Systematic Review and Meta-analysis. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 5. pp. 1686-1693.
@article{0c316f2c03c44169b443a7d1ea391e3d,
title = "Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis",
abstract = "Background: Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature. Methods: The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots. Results: Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49–55), with 59 {\%} (54–67) female. The median peritoneal carcinomatosis index score was 19 (16–23). Complete cytoreduction (CC0, 1) was performed in 67 {\%} (46–93 {\%}) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 {\%}, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 {\%}) and those receiving cisplatin intraperitoneal chemotherapy alone (48 {\%}) or in combination (44 {\%}) had an improved 5-year survival. Conclusions: While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.",
author = "Helm, {Joseph H.} and Miura, {John T.} and Glenn, {Jason A.} and Marcus, {Rebecca K.} and Gregory Larrieux and Jayakrishnan, {Thejus T.} and Donahue, {Amy E.} and Gamblin, {T. Clark} and Turaga, {Kiran K.} and Fabian Johnston",
year = "2015",
month = "5",
day = "1",
doi = "10.1245/s10434-014-3978-x",
language = "English (US)",
volume = "22",
pages = "1686--1693",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

T2 - A Systematic Review and Meta-analysis

AU - Helm, Joseph H.

AU - Miura, John T.

AU - Glenn, Jason A.

AU - Marcus, Rebecca K.

AU - Larrieux, Gregory

AU - Jayakrishnan, Thejus T.

AU - Donahue, Amy E.

AU - Gamblin, T. Clark

AU - Turaga, Kiran K.

AU - Johnston, Fabian

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature. Methods: The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots. Results: Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49–55), with 59 % (54–67) female. The median peritoneal carcinomatosis index score was 19 (16–23). Complete cytoreduction (CC0, 1) was performed in 67 % (46–93 %) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 %, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 %) and those receiving cisplatin intraperitoneal chemotherapy alone (48 %) or in combination (44 %) had an improved 5-year survival. Conclusions: While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.

AB - Background: Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature. Methods: The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots. Results: Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49–55), with 59 % (54–67) female. The median peritoneal carcinomatosis index score was 19 (16–23). Complete cytoreduction (CC0, 1) was performed in 67 % (46–93 %) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 %, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 %) and those receiving cisplatin intraperitoneal chemotherapy alone (48 %) or in combination (44 %) had an improved 5-year survival. Conclusions: While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.

UR - http://www.scopus.com/inward/record.url?scp=84936848841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936848841&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-3978-x

DO - 10.1245/s10434-014-3978-x

M3 - Review article

C2 - 25124472

AN - SCOPUS:84936848841

VL - 22

SP - 1686

EP - 1693

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -